// App-Quantinova.ai

SO-4 : phase Ib/II, open-label, randomised evaluation of atezolizumab plus RO6874281 vs control in MORPHEUS–pancreatic ductal adenocarcinoma

Researchers

Presenter

  • V. Chung

Principal Investigators

  • A. Alistar

  • B. George

  • K. Kim

  • H. Kindler

  • D. Oh

  • S. Allen

  • H. Barak

  • B. Ci

  • J. Lau

  • A. Retiere

  • C. Shemesh

  • V. Teichgrber

  • X. Zhang

  • C. Lopez

Medical Centers

  • Morristown Medical Center, Morristown, NJ, United States

  • Medical College of Wisconsin, Milwaukee, Wisconsin , United States

  • Asan Medical Center, University of Ulsan, Seoul, South Korea

  • University of Chicago, Chicago, IL, United States

  • Genentech Inc., San Francisco, United States

  • F. Hoffmann-La Roche, Welwyn Garden City, United Kingdom

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Portland VA Medical Center and Oregon Health & Science University, Portland, Oregon, United States

Locations

  • United States

  • Republic of South Korea

  • United Kingdom

  • Switzerland

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreas ductal adenocarcinoma

  • Microphthalmia, syndromic, 9

Biomarkers

  • N/A

Drug/Treatment

  • Atezolizumab

  • Gemcitabine

  • Paclitaxel

  • mFOLFOX6

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved